Amryt Pharma is dedicated to developing innovative medicines aimed at treating rare and debilitating diseases. The company focuses on transforming the lives of patients and their families by acquiring, developing, and commercializing therapies that address unmet medical needs. Their approach combines deep scientific knowledge with a commitment to responsible and rapid access to new treatments, ensuring that patients and caregivers can benefit from advancements in medical science. This commitment is reflected in their collaboration with advocacy groups to support patients and their families in navigating the challenges associated with rare diseases.

The product portfolio of Amryt Pharma includes specialized therapies such as Juxtapid® (lomitapide), Myalept® (metreleptin), and Mycapssa® (octreotide), each targeting specific rare conditions like homozygous familial hypercholesterolemia, lipodystrophy, and acromegaly, respectively. By focusing on these niche areas, Amryt Pharma aims to deliver safe and effective treatments that can significantly improve the quality of life for individuals affected by these conditions. Their ongoing commitment to innovation and patient care positions them as a leader in the rare disease space, striving to make a meaningful impact on global health.

Ireland

Amryt Pharma was acquired by Chiesi Farmaceutici S.p.A. (“Chiesi”) April 12, 2023. Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.

Endocrine System Diseases

Genetic Diseases

Metabolic Diseases

Musculoskeletal Diseases

Nervous System Diseases

Rare diseases

Skin Diseases

Amryt Pharma

Acromegaly

Hormone disorder

Octreotide exerts pharmacologic actions similar to the natural hormone somatostatin, but is a more potent inhibitor of GH, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses luteinizing hormone (LH) response to gonadotropin-releasing hormone (GnRH), decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide.

Mycapssa (octreotide)

Homozygous familial hypercholesterolemia

Pulmonary arterial hypertension

JUXTAPID directly binds and inhibits microsomal triglyceride transfer protein (MTP), which resides in the lumen of the endoplasmic reticulum, thereby preventing the assembly of apo B-containing lipoproteins in enterocytes and hepatocytes. This inhibits the synthesis of chylomicrons and VLDL. The inhibition of the synthesis of VLDL leads to reduced levels of plasma LDL-C.

Juxtapid/Lojuxta (lomitapide) 

Generalized lipodystrophy

Rare genetic disease

MYALEPT (metreleptin) for injection exerts its function by binding to and activating the human leptin receptor (ObR), which belongs to the Class I cytokine family of receptors that signals through the JAK/STAT transduction pathway.

Myalept (metreleptin injections) 

Europe - West

Small Molecule Pharmaceuticals

Therapeutic

Amryt Pharma

Company Details